Clearmind Medicine Inc. (CMND) Form 6-K — Jul 30, 2026
Clearmind Medicine Inc. announced positive safety findings from Part A of its FDA-regulated Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder. The study successfully achieved its primary endpoint of safety and tolerability across four ascending-dose cohorts. All 24 participants completed treatment as planned, with no serious adverse events observed even at the highest dose level of 160 mg.
Key figures
- Cohort Count
- 4
- Participants
- 24
- Granted Patents
- 32
- Patent Families
- 19
- Dose Levels
- 20 mg, 40 mg, 80 mg, 160 mg
- Study Phase
- Phase I/II
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.